Brief: Prelude Therapeutics, Inc. posts Q2 EPS USD -0.54
03/08/2023 13:04
Aug 3 (Reuters) - Prelude Therapeutics, Inc. Q2 net income USD -30.431 million. * Q2 income from operations USD -32.398 million * Q2 operating expenses USD 32.398 million * Q2 EPS USD -0.54
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview